Breast cancer 1, early onset (BRCA1) is a well-known tumor suppressor gene that was originally discovered due to its link with early-onset breast and ovarian cancer in women. The BRCA1 protein contains the following domains: RING finger, RAD51-interaction, and BRCT (BRCA1 C-terminus). The N-terminus RING domain enables binding to several proteins - including BARD1 (BRCA1-associated RING domain protein) - allowing the formation of heterodimers. The RING finger is important for tumor suppressor activity. The RAD51-interaction domain is involved in DNA double-stranded break (DSB) repair. The loss of RAD51 binding increases cancer risk due to increased increments of damaged DNA. The BRCT functions as a transcriptional activation domain and is involved in cell-cycle control and DNA repair. BRCA1 has been implicated in a wide range of cancer-related activities, such as cell cycle progression, DNA repair, DNA damage-responsive cell cycle checkpoints, transcription regulation, ubiquitination, chromosome remodeling, and apoptosis. BRCA1 defects within an individual’s genome increases the likelihood of occurrence of breast cancer, familial breast-ovarian cancer type 1 (BROVCA1), ovarian cancer, and pancreatic cancer type 4 (PNCA4).
-Western-Blot-NBP1-41185-img0007.jpg)
Western Blot: BRCA1 Antibody
Okada et al paired confocal microscopy and immunoblotting with BRCA1 antibody to monitor how cell cycle differences in BRCA1 phosphorylation affect its subcellular localization1. Oncologists employed the BRCA1 antibody in their ataxia telangiectasia mutated (ATM) model to closely examine DNA damage and the triggered assembly of BRCA1, BAAT1, and ATM2. Genomic research from Kluk’s group relied upon the BRCA1 antibody to help them confirm expression of BRCA1 and an isoform of the DLX4 homeobox gene (BP1) in familial versus sporadic breast cancers3. Their studies suggest that BP1 plays an important role in negatively regulating BRCA1 and further work is needed to see if BP1 is a usable drug therapy target. Marin et al from UCLA used the BRCA1 antibody in their assessments of radiosensitivity using kinetic profiles4. They believe they have identified a means of globally identifying defective DNA repair pathways in radiosensitive cells. Recent results from Canada used BRCA1 antibody immunofluorescence to detect alternation open reading frames (ORFs) translation products by subjecting a synthesized proteome database to mass spectrometry5.
Novus Biologicals offers BRCA1 reagents for your research needs including:
PMIDs
